Introduction
Materials and methods
Study population
Diagnostic evaluations
Definitions
Data collection
Statistical analysis
Results
Total (n= 214) | Hematologic (n= 115, 54%) | Solid (n= 99, 46%) | P value | |
---|---|---|---|---|
Age (years) | 60 (51-68) | 56 (44-67) | 62 (56-69) | 0.002 |
Gender (male) | 144 (67) | 77 (67) | 67 (68) | 0.911 |
Co-morbidities | 111 (52) | 59 (51) | 52 (53) | 0.859 |
Cardiovascular | 40 | 19 | 21 | |
Respiratory | 25 | 11 | 14 | |
Hepatic | 10 | 4 | 6 | |
Renal | 4 | 3 | 1 | |
Diabetes | 2 | 2 | 0 | |
Othersa | 15 | 12 | 3 | |
ECOG performance status (3 or more) | 61 (28) | 35 (30) | 26 (26) | 0.500 |
Type of malignancy | ||||
Solid | 98 (46) | |||
Hematologic | 116 (54) | |||
Status of malignancy | ||||
Relapsed/refractory | 64 (30) | 34 (30) | 30 (30) | 0.906 |
Extensive disease or major organ involvement | 151 (71) | 66 (58) | 85 (86) | <0.001 |
Stem cell transplantation | 28 (13) | 28 (24) | 0 | |
Allogenic | 11 | 11 | ||
Autologous | 17 | 17 | ||
Duration of malignancy, months | 8.2 (2.9-19.4) | 7.4 (2.6-18.2) | 8.5 (3.1-24.0) | 0.154 |
Clinical status on ICU admission | ||||
Antibacterial agents | 210 (98) | 115 (100) | 95 (96) | 0.044 |
Recent chemotherapy prior to ICU admission within 4 weeks | 89 (42) | 45 (39) | 44 (44) | 0.487 |
Need for mechanical ventilationb | 109 (51) | 43 (37) | 66 (67) | <0.001 |
Need for vasopressor support | 52 (24) | 28 (24) | 24 (24) | 0.986 |
Need for renal replacement therapy | 19 (9) | 16 (14) | 3 (3) | 0.005 |
Laboratory findings | ||||
WBC,/μL | 6,305 (2,250-12,378) | 3,030 (730-7,280) | 10,220 (5,330-15,670) | <0.001 |
ANC,/μL | 3,970 (995-8,545) | 1,700 (240-4,570) | 7,520 (3380-12,680) | <0.001 |
Neutropenia (ANC <500/μL) | 40 (18) | 32 (28) | 8 (8) | <0.001 |
Platelet, 103/μL | 112.5 (29.0-234.8) | 35.0 (16.0-117.0) | 187.0 (116.0-271.0) | <0.001 |
CRP, mg/dL | 14.8 (7.4-22.3) | 12.1 (5.5-19.8) | 16.2 (10.4-24.0) | 0.003 |
Procalcitonin, ng/mL | 0.65 (0.19-2.85) | 0.72 (0.19-3.70) | 0.56 (0.17-2.29) | 0.443 |
pH | 7.444 (7.375-7.474) | 7.452 (7.400-7.483) | 7.433 (7.362-7.465) | 0.017 |
NT-proBNP, pg/mL | 1392 (273-4796) | 2,108 (445-8,780) | 940 (239 - 3424) | 0.035 |
PF ratio | 145 (105-214) | 160 (109-234) | 134 (101 - 181) | 0.075 |
Severity of illness | ||||
SAPS 3 (points) | 61 (50-75) | 65 (52-78) | 58 (48-66) | 0.002 |
SOFA score (points) | 6 (3-8) | 6 (4-9) | 5 (3-8) | 0.013 |
Length of stay in ICU (days) | 6 (3-13) | 5 (2-10) | 7 (3-16) | 0.012 |
Length of stay in hospital (days) | 26 (15-44) | 31 (17-59) | 21 (12-34) | 0.002 |
ICU mortality | 64 (30) | 33 (29) | 31 (31) | 0.765 |
In-hospital mortality | 105 (49) | 55 (48) | 50 (51) | 0.784 |
90-day mortality | 138 (65) | 68 (59) | 70 (71) | 0.087 |
Patients, n(%) | |
---|---|
Non-invasive tests | |
Blood cultures for bacteria | 214 (100) |
Sputum examination for bacteria | 214 (100) |
Sputum examination for fungi | 214 (100) |
Sputum examination for mycobacteria | 210 (98) |
Urine Streptococcus pneumonia antigen | 186 (87) |
Urine Legionella pneumophila antigen | 108 (50) |
Serum mycoplasma antibody | 159 (74) |
Serum Aspergillus galactomannan assay | 95 (44) |
CMV antigenemia | 94 (44) |
Chest CT scans | 209 (98) |
Echocardiography | 24 (11) |
Invasive tests | |
Fiberoptic bronchoscopy | 160 (75) |
BALa | 160 |
TBLB | 75 |
Surgical lung biopsy | 6 (3) |
Etiologies | Diagnostic probability (n= 214) | Hematologic (n = 115) | Solid (n = 99) | ||||
---|---|---|---|---|---|---|---|
Total
|
Definite
|
Probable
|
Definite
|
Probable
|
Definite
|
Probable
| |
Infectious etiologies | 138 (64) | 58 (27) | 80 (37) | 31 (27) | 51 (44) | 27 (27) | 29 (29) |
Bacterial | 63 (29) | 28 (13) | 35 (16) | 14 (12) | 15 (13) | 14 (14) | 20 (20) |
Viral | 39 (18) | 9 (4) | 30 (14) | 4 (3) | 23 (20) | 5 (5) | 7 (7) |
Fungal | 19 (9) | 4 (2) | 15 (7) | 2 (2) | 13 (11) | 2 (2) | 2 (2) |
P. jiroveci | 14 (7) | 14 (7) | 0 | 10 (9) | 0 | 4 (5) | 0 |
Tuberculosis | 3 (1) | 3 (1) | 0 | 1 (1) | 0 | 2 (2) | 0 |
Non-infectious etiologies | 49 (23) | 24 (11) | 25 (12) | 10 (9) | 8 (7) | 14 (14) | 17 (17) |
Metastasis | 12 (6) | 12 (6) | 0 | 1 (1) | 0 | 11 (11) | 0 |
Diffuse alveolar hemorrhage | 8 (4) | 8 (4) | 0 | 6 (5) | 0 | 2 (2) | 0 |
Cardiogenic pulmonary edema | 10 (5) | 3 (1) | 7 (3) | 2 (2) | 5 (4) | 1 (1) | 2 (2) |
Drugs | 13 (6) | 0 | 13 (6) | 0 | 2 (2) | 0 | 11 (11) |
Othersa | 6 (3)a | 1 (0) | 5 (2) | 1 (1) | 1 (1) | 0 | 4 (4) |
Total | 187 (87) | 82 (38) | 105 (49) | 41 (36) | 59 (51) | 42 (42) | 46 (47) |
Survivor (n= 109, 51%) | Non-survivor (n= 105, 49%) | Odds ratio (95% CI) | P value | |
---|---|---|---|---|
Age (years) | 59 (51-66) | 62 (51-69) | 1.007 (0.998-1.027) | 0.477 |
Gender (male) | 71/144 (49) | 73/144 (51) | 1.221 (0.689-2.165) | 0.494 |
Co-morbidity | 51/111 (46) | 60/111 (54) | 1.516 (0.884-2.600) | 0.130 |
Type of malignancy | ||||
Hematology | 60/115 (52) | 55/115 (48) | 0.898 (0.525-1.538) | 0.696 |
ECOG performance status (3 or more) | 22/61 (36) | 39/61 (64) | 2.337 (1.266-4.313) | 0.006 |
Status of malignancy | ||||
Relapsed/refractory | 24/64 (38) | 40/64 (63) | 2.179 (1.196-3.973) | 0.010 |
Extensive or major organ involvement | 76/151 (50) | 75/151 (50) | 1.086 (0.603-1.955) | 0.785 |
Stem cell transplantation | 9/28 (32) | 19/28 (68) | 2.455 (1.056-5.708) | 0.033 |
Duration of malignancy, months | 9.8 (3.1-22.5) | 6.9 (2.7-18.4) | 0.997 (0.989-1.005) | 0.486 |
Clinical status on ICU admission | ||||
Recent chemotherapy | 88/182 (48) | 94/182 (52) | 2.039 (0.930-4.472) | 0.071 |
Need for mechanical ventilationa | 44/109 (40) | 65.109 (60) | 2.401 (1.386-4.157) | 0.002 |
Need for vasopressor support | 20/52 (39) | 32/52 (62) | 1.951 (1.030-3.695) | 0.039 |
Need for renal replacement therapy | 8/19 (42) | 11/19 (58) | 1.477 (0.570-3.832) | 0.42 |
Neutropenia | 12/40 (30) | 28/40 (70) | 2.939 (1.403-6.157) | 0.003 |
Severity of illness | ||||
SAPS 3 (points) | 59 (50-72) | 64 (50-76) | 1.016 (1.001 - 1.032) | 0.0420 |
SOFA score (points) | 5 (3-7) | 7 (4-9) | 1.125 (1.033 - 1.226) | 0.007 |
Identified etiology | 96/187 (51) | 91/187 (49) | 0.880 (0.393 - 1.974) | 0.757 |
Therapeutic modification | 61/99 (62) | 38/99 (38) | 0.446 (0.258 - 0.773) | 0.004 |
Adjusted OR (95% CI) | P value | |
---|---|---|
Therapeutic modification | 0.509 (0.281-0.920) | 0.025 |
ECOG performance status (3 or more) | 1.973 (1.027-3.791) | 0.041 |
Stem cell transplantation | 3.041 (1.242-7.447) | 0.015 |
Need for mechanical ventilation | 2.374 (1.320-4.270) | 0.004 |
Neutropenia | 2.464 (1.133-5.358) | 0.023 |
Hematologic (n= 115, 54%) | Solid (n= 99, 46%) | P value | |
---|---|---|---|
Therapeutic modification | 62 (54) | 37 (37) | 0.016 |
Initiation of antimicrobial agents | 40 | 19 | |
Change of antimicrobial agents | 8 | 1 | |
Withdrawal of antimicrobial agents | 10 | 5 | |
Initiation of steroid | 3 | 11 | |
Initiation of chemotherapy | 1 | 1 | |
End-of-life decision | 0 | 10 (10) | <0.001 |
Outcomes | |||
ICU mortality | 33 (29) | 31 (31) | 0.677 |
Length of stay in ICU (days) | 5 (2-10) | 7 (3-16) | 0.008 |
In-hospital mortality | 55 (48) | 50 (51) | 0.696 |
Length of stay in hospital (days) | 31 (17-59) | 22 (12-34) | 0.004 |
90-day mortality | 68 (59) | 70 (71) | 0.078 |
Discussion
Conclusions
Key messages
-
The etiologies of diffuse pulmonary infiltrates causing acute respiratory failure in cancer patients could be identified in the majority of the patients.
-
Invasive tests including bronchoalveolar lavage and transbronchial lung biopsy in combination with non-invasive tests additionally provided etiologic diagnoses of diffuse pulmonary infiltrates.
-
Therapeutic modification based on the etiologic diagnosis was significantly associated with lower in-hospital mortality in cancer patients with diffuse pulmonary infiltrates.